Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...
The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...
Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...
Although the majority of claims involved COVID-19 medicines, most of the funds — $6.1 million — went to deaths and injuries caused by the H1N1 vaccine, such as Guillain-Barré syndrome.
Credit: Shutterstock / Mdisk Swedish biotechnology firm Hansa Biopharma has announced that its investigational drug imlifidase improved motor function in patients with Guillain-Barré Syndrome (GBS) in ...
The Background Rates of Adverse Events for Vaccine Evaluation in Africa project will look to understand the incidence rates of naturally occurring clinical events within African populations such as ...